Linshom fills the $2B+ need (US only) for patients at risk of respiratory depression that require continuous respiratory monitoring (CRM). Current technology in the OR and ICU is not transferable and fails at this critical task. Linshom’s, FDA cleared, non-invasive, portable respiratory monitor meets the growing mandate for CRM; particularly those receiving opioids, suffering from apnea, or requiring supplemental oxygen.